Notícias e Atividades da Protagonist Therapeutics

Protagonist Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Protagonist Therapeutics é uma empresa listada sob o símbolo PTGX (US).

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Protagonist Therapeutics

• Dinesh Patel, Director, President and Chief Executive Officer
• Lewis Williams, Director
• Bryan Giraudo, Director

Criar um alerta
para seguir os movimentos de executivos da Protagonist Therapeutics.

Protagonist Therapeutics possui 2.351 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Protagonist Therapeutics

• Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera | Protagonist Therapeutics, Inc.
• Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020 | Protagonist Therapeutics, Inc.
• Protagonist Therapeutics Reports Granting of Inducement Award | Protagonist Therapeutics, Inc.
• Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference | Protagonist Therapeutics, Inc.
• Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar | Protagonist Therapeutics, Inc.
• Protagonist Appoints Sarah O'Dowd to Board of Directors | Protagonist Therapeutics, Inc.
• Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update | Protagonist Therapeutics, Inc.
• Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera | Protagonist Therapeutics, Inc.
• Press Releases | Protagonist Therapeutics, Inc.
• Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference | Protagonist Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Protagonist Therapeutics

• Protagonist Therapeutics na Wikipedia, Google News e Yahoo Finance
• Protagonist Therapeutics na LinkedIn, Twitter e YouTube